For far too long, the treatment needs of women with HIV have been given short shrift -- by doctors, researchers, drug companies and community organizations alike. Because human biology differs by gender, women face a wide range of problems not covered by “general” medical information based only on research in men. After much activist struggle, some meager studies of women’s disease progression are under way. But it’s still rare that an AIDS drug trial includes enough women to uncover possible gender differences in dosage, effectiveness and toxicity. Pushing for this inclusion, and for more studies that mine the rich lode of women PWAs’ experiences, are key tasks for everyone concerned about AIDS.
September 1, 1997 • By Bob Lederer